What is HC Wainwright’s Estimate for Zymeworks Q2 Earnings?

Zymeworks Inc. (NASDAQ:ZYME) – Investment analysts at HC Wainwright lowered their Q2 2026 EPS estimates for shares of Zymeworks in a research note issued on Wednesday, August 5th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.58) for the quarter, down from their previous forecast of ($0.29). HC Wainwright has a “Buy” rating and a $51.00 price objective on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Zymeworks’ Q4 2026 earnings at ($0.54) EPS and FY2026 earnings at $0.36 EPS.

Zymeworks (NASDAQ:ZYME) last released its earnings results on Thursday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.05). The company had revenue of $4.59 million during the quarter, compared to the consensus estimate of $3.81 million. Zymeworks had a negative return on equity of 37.97% and a negative net margin of 126.92%.Zymeworks’s revenue for the quarter was down 90.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.03 EPS.

Several other brokerages have also weighed in on ZYME. Wells Fargo & Company boosted their price objective on Zymeworks from $34.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Truist Financial lifted their target price on Zymeworks from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Citigroup reiterated a “buy” rating on shares of Zymeworks in a report on Tuesday, June 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zymeworks currently has an average rating of “Moderate Buy” and a consensus target price of $37.89.

Zymeworks Stock Performance

Shares of ZYME stock opened at $23.13 on Friday. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of -16.88 and a beta of 1.15. Zymeworks has a one year low of $11.51 and a one year high of $29.75. The company’s 50-day simple moving average is $24.02 and its 200-day simple moving average is $24.46.

Hedge Funds Weigh In On Zymeworks

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Kornitzer Capital Management Inc. KS acquired a new stake in Zymeworks in the 4th quarter valued at approximately $2,338,000. Rubric Capital Management LP raised its stake in Zymeworks by 21.7% during the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock valued at $175,280,000 after acquiring an additional 1,250,000 shares in the last quarter. Vanguard Group Inc. boosted its position in Zymeworks by 8.1% during the 4th quarter. Vanguard Group Inc. now owns 2,328,727 shares of the company’s stock worth $61,315,000 after acquiring an additional 174,293 shares during the period. Pictet Asset Management Holding SA acquired a new position in Zymeworks during the 4th quarter worth $1,966,000. Finally, SummitTX Capital L.P. grew its stake in shares of Zymeworks by 43.3% in the first quarter. SummitTX Capital L.P. now owns 321,427 shares of the company’s stock worth $8,049,000 after purchasing an additional 97,159 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Zymeworks declared that its Board of Directors has approved a share repurchase plan on Thursday, May 14th that allows the company to buyback $125.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 7% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.